Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
返回论文页
Short communication|更新时间:2023-08-29
|
Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
Genes & DiseasesVol. 10, Issue 5, (2023)
作者机构:
1. Department of Dermatology, University of Utah,UT,Salt Lake City,USA,84132
2. Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,201900
3. Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125
4. Department of Oral & Maxillofacial - Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125
5. Huntsman Cancer Institute,UT,Salt Lake City,USA,84112
6. Department of Oncology, The Third People's Hospital of Zhengzhou
Ruixin Jiang, Xianbin Liang, Ye Tao, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. [J]. Genes & Diseases 10(5).(2023)
DOI:
Ruixin Jiang, Xianbin Liang, Ye Tao, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. [J]. Genes & Diseases 10(5).(2023) DOI: 10.1016/j.gendis.2022.11.014.
Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma